Pfizer names Cecile Guegan chief financial officer
Pfizer Inc. has appointed Cecile Guegan as chief financial officer and executive vice president, effective November 1, 2026.

PFE Health Care · 2 analyses · 15 expectations tracked
Pfizer reported $16.6B in revenue (-0.4% YoY), compared with a +7.2% median across covered Health Care peers. Insider tracks 15 open management expectations for this company. Its latest periodic filing added 25 new risk factors.
Pfizer Inc. has appointed Cecile Guegan as chief financial officer and executive vice president, effective November 1, 2026.
Pfizer reported third-quarter 2026 revenue of $16.6 billion and adjusted diluted earnings per share (EPS) of $0.87. Total revenue fell $71 million from the year-ago period. The company noted 7% operational growth in its portfolio excluding Comirnaty and Paxlovid.
From the 10-Q for the period ended September 27, 2026, filed November 3, 2026. SEC
| Latest | Earlier | Change | |
|---|---|---|---|
| Revenue quarter | $16.6B | $16.7B | -0.4% |
| Net income quarter | $3.2B | $3.5B | -8.4% |
| Diluted EPS quarter | $0.56 | $0.62 | -9.7% |
| Dividends per share quarter | $0.00 | $0.00 | — |
| Operating cash flow year to date | $8.8B | $6.4B | +38.8% |
| Cash and cash equivalents balance | $1.8B | $1.1B | +59.7% |
| Long-term debt balance | $60B | $61.6B | -2.7% |
As the company tagged them in its filing (SEC XBRL). Quarter and year figures are compared with the same period a year earlier, balances with the previous balance sheet. Download CSV
Revenue by quarter, $B
How this company compares with 36 covered companies in Health Care (median revenue change +7.2% YoY), from archived SEC XBRL filings.
| Company | Latest revenue | Revenue YoY | Operating margin |
|---|---|---|---|
| Pfizer Inc PFE | $16.6B | -0.4% | — |
| Unitedhealth Group Inc UNH | $113B | -0.4% | 5.8% |
| Mckesson Corp MCK | $111B | +7.6% | 1.4% |
| CVS Health Corp CVS | $108B | +5.4% | 3.3% |
| Cigna Group CI | $73.7B | +5.6% | 3.3% |
| Cardinal Health Inc CAH | $67.5B | +5.5% | 1.1% |
| Elevance Health, Inc. ELV | $51.4B | +1.4% | 2.5% |
Latest reported period per company from SEC CompanyFacts (XBRL). Fiscal calendars differ across companies.
The company does not currently anticipate the availability of raw materials to have a significant impact on operations in 2026.
Not yet checked against later reports.
The company expects an unfavorable revenue impact of approximately $1.1 billion in 2026 due to patent-based or regulatory exclusivity expiries.
Not yet checked against later reports.
The company anticipates a significant reduction of revenue from patent-based or regulatory exclusivity expiries between 2026 and 2030.
Not yet checked against later reports.
The company anticipates an unfavorable revenue impact of approximately $1.1 billion due to generic and biosimilar competition.
Not yet checked against later reports.
The company does not expect a material, incremental impact from the IRA Medicare Part D Redesign in 2026 versus the 2025 baseline.
Not yet checked against later reports.
Pfizer expects to incur one-time costs of approximately $2.0 billion to achieve the additional savings from the Realigning Our Cost Base Program through 2029.
Not yet checked against later reports.
Pfizer expects its Manufacturing Optimization Program to deliver additional anticipated savings of approximately $1.5 billion from 2027 through 2029.
Not yet checked against later reports.
Full-year 2026 financial guidance does not assume the completion of any business development transactions not completed as of November 3, 2026.
Not yet checked against later reports.
Guidance for Adjusted diluted EPS assumes diluted weighted-average shares outstanding of approximately 5.74 billion shares and no share repurchases.
Not yet checked against later reports.
Pfizer expects one-time costs to achieve savings for the Manufacturing Optimization Program to total approximately $4.0 billion, with about 60% being non-cash expenditures, incurred through 2029.
Not yet checked against later reports.
Current financial guidance does not anticipate any share repurchases in 2026.
Not yet checked against later reports.
Full-year 2026 Adjusted diluted EPS guidance raised and narrowed to a range of $2.95 to $3.05.
Not yet checked against later reports.
The HHS 340B pilot program is expected to begin in January 2027 and include Eliquis, Ibrance and Xtandi.
Not yet checked against later reports.
Full-year 2026 Revenue guidance raised to a range of $62.0 to $64.0 billion.
Not yet checked against later reports.
Effective tax rate on Adjusted income is expected to be approximately 15.0%.
Not yet checked against later reports.
What management said to expect (targets, plans, forecasts) in the company's own documents (in English, as extracted), with the date and the period it named. Assessments are written by AI from the company's later reports: provisional, not checked by an editor, and a consistent later report is not proof. An editor's decision replaces them.
The 10-Q filed November 3, 2026 compared with the 10-Q filed August 4, 2026: risk paragraphs that were added or dropped, quoted as filed. SEC
Found by comparing the two reports paragraph by paragraph, without AI. A new or dropped risk is not by itself a sign of trouble.
Filings about how the company is run: auditor changes, restatements, leadership changes, late filings, delistings, Schedule 13D stakes and SEC comment letters, newest first.
| Date | Event | Filing |
|---|---|---|
| November 3, 2026 | Director or officer departure or appointment (8-K item 5.02) | 8-K |
As filed with the SEC, read by code. A comment letter is part of the SEC staff’s routine review and does not by itself mean a problem; item 5.02 covers appointments as well as departures; Form 25 may concern a bond or another class of securities.
| Fund | Shares | Value | Change in shares | Quarter |
|---|---|---|---|---|
| BlackRock | 521,032,629 | $14,859,850,573 | -1.6% | Q3 2026 |
| State Street | 309,573,847 | $8,829,046,116 | +0.8% | Q3 2026 |
| Geode Capital Management | 137,506,393 | $3,907,781,638 | +1.6% | Q3 2026 |
| Norges Bank (Norway's sovereign fund) | 61,505,586 | $1,481,054,511 | — | Q2 2026 |
| Fidelity (FMR) | 18,004,331 | $513,483,530 | +16.9% | Q3 2026 |
| D. E. Shaw & Co. | 16,584,679 | $472,995,045 | +206.3% | Q3 2026 |
| Wellington Management | 11,244,339 | $320,688,548 | -59.6% | Q3 2026 |
| Two Sigma Investments | 6,419,852 | $183,094,179 | +1,843.6% | Q3 2026 |
| Citadel Advisors | 4,741,501 | $135,227,609 | -23.4% | Q3 2026 |
| Renaissance Technologies | 1,989,077 | $56,728,501 | — | Q3 2026 |
| Millennium Management | 1,739,069 | $49,598,248 | +212.7% | Q3 2026 |
| Bridgewater Associates | 477,929 | $13,630,535 | +165.4% | Q3 2026 |
| T. Rowe Price | 9,266,055 | $264,269 | -36.2% | Q3 2026 |
From the quarterly 13F-HR holdings reports of the large funds we follow, as filed. Funds file up to 45 days after the quarter ends, so positions may have changed since. Change: against the same fund's previous quarter. Not a recommendation.